AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30159739
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific postoperative therapy (control group)
Trial: 29049469
Drug: Extended-release naltrexone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone, 380 mg, administered intramuscularly every fourth week for 12 weeks
Trial: 29049469
Drug: Buprenorphine-naloxone, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone, daily oral flexible dose 4 to 24 mg/d
Trial: 26081066
Drug: NT‐proBNP concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP concentrations in women who developed CVD (81 ng/l [50 to 147])
Trial: 29944164
Drug: High SPF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High SPF sunscreen applied at 1.3 mg/cm2
Trial: 29944164
Drug: High SPF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High SPF sunscreen applied at 2.0 mg/cm2
Trial: 29944164
Drug: High SPF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High SPF sunscreen applied at 0.75 mg/cm2
Trial: 24956119
Drug: MBL-HCV1 treatment
RxNorm normalized name: MBL-HCV1
DrugBank: MBL-HCV1 (DB17776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBL-HCV1 treatment
Trial: 15670539
Drug: Trimetazidine plus
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine plus sildenafil (sildenafil 100 mg 1 hour before sexual intercourse, trimetazidine 20 mg 3 times a day)
Trial: 15670539
Drug: Nitrates (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates (20 mg 3 times a day)
Trial: 12075057
Drug: Fumagillin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumagillin (60 mg per day orally for two weeks)
Trial: 2245418
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation training before chemotherapy
Trial: 31732149
Drug: Xhance® 186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xhance® 186 μg
Trial: 31732149
Drug: Xhance® 372
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xhance® 372 μg
Trial: 31732149
Drug: Flonase® 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flonase® 400 μg
Trial: 31732149
Drug: Flovent® HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flovent® HFA 440 μg
Trial: 23243239
Drug: BD supplemented
RxNorm normalized name: BD-111
DrugBank: BD-111 (DB18247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD supplemented with 2.5 mg of AFB(1)/kg of feed and 0.5% HSCAS
Trial: 23243239
Drug: BD supplemented
RxNorm normalized name: BD-111
DrugBank: BD-111 (DB18247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD supplemented with 2.5 mg of AFB(1)/kg of feed
Trial: 20628180
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 250 mg given thrice weekly
Trial: 19841338
Drug: Prednisolone for
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone for 2 weeks (monotherapy)
Trial: 19841338
Drug: Prednisolone for
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone for 2 weeks plus Ginkgo biloba for 4 weeks (combination therapy)
Trial: 17075269
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline 5-8 mg/kg (dry syrup) or 100-200 mg (tablet) twice daily
Trial: 11230586
Drug: No cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cooling (rectal temperature = 37.0 +/- 0.2 degrees C, n = 15)
Trial: 11230586
Drug: Minimally cooled
RxNorm normalized name: INSERTER,MINIMED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally cooled (rectal temperature 36.5 degrees C to 36 degrees C, n = 6)
Trial: 11230586
Drug: Mildly cooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly cooled (rectal temperature 35.9 degrees C to 35.5 degrees C, n = 6)
Trial: 11230586
Drug: Mildly cooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly cooled (rectal temperature 35 +/- 0.5 degrees C, n = 6)
Trial: 11230586
Drug: Mildly cooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly cooled (rectal temperature 34.5 +/- 0.5 degrees C, n = 7)
Trial: 2535298
Drug: Sufentanil, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil, 5 micrograms/kg, IV with succinylcholine, 1 mg/kg, IV
Trial: 2535298
Drug: Etomidate, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate, 0.4 mg/kg, IV with succinylcholine, 1 mg/kg, IV
Trial: 1095310
Drug: Clotrimazole therapy
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole therapy
Trial: 30595354
Drug: Fluvoxamine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (250 mg daily) plus MPH-ER (36 mg daily)
Trial: 30595354
Drug: Fluvoxamine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (250 mg daily) plus placebo
Trial: 26509366
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.3 g/kg/d during 7 days)
Trial: 23073950
Drug: High-dose multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at high levels)
Trial: 23073950
Drug: Standard-dose multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at standard levels)
Trial: 23073950
Drug: High-dose multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multivitamin supplementation
Trial: 23073950
Drug: Standard-dose multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose multivitamin supplementation
Trial: 21708060
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 14 days
Trial: 15934992
Drug: IV magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV magnesium (0.2 mg Mg per mL acid citrate dextrose‐A)
Trial: 12425542
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Lactobacillus spp. and bifidobacteria
Trial: 10075273
Drug: Delavirdine in
RxNorm normalized name: Product containing delavirdine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine in combination with zidovudine
Trial: 10075273
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with zidovudine
Trial: 2024973
Drug: Ofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (400 mg) administered as a 1-h infusion
Trial: 2024973
Drug: Ofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (400 mg) administered as an oral tablet
Trial: 2024973
Drug: Oral dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosage form of ofloxacin
Trial: 6344900
Drug: M&B 22,948
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M&B 22,948 (10 mg)
Trial: 30402473
Drug: Zearalenone (ZEA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zearalenone (ZEA) 400 μg/kg.b.w
Trial: 30402473
Drug: Zearalenone (ZEA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zearalenone (ZEA) 800 μg/kg.b.w
Trial: 30402473
Drug: Zearalenone (ZEA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zearalenone (ZEA) 1600 μg/kg.b.w
Trial: 26823611
Drug: Low-dose alcohol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcohol (approximately 0.065% peak breath alcohol concentration)
Trial: 22492127
Drug: Interferon beta‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1b (IFNβ‐1b) 250 µg
Trial: 19747410
Drug: Fermented dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented dairy product containing Lactobacillus casei DN-114001 (200 g/d)
Trial: 10472396
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention including information on doping, discussions on nutritional supplements, drug simulating role play, and self-medication information.
Trial: 8598548
Drug: Kunitz trypsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kunitz trypsin inhibitor
Trial: 8598548
Drug: Bowman‐Birk inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowman‐Birk inhibitor
Trial: 26016936
Drug: Alternative Perfusion
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative Perfusion Solution (APS)
Trial: 24039213
Drug: Sunglasses worn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunglasses worn during daytime in addition to topical aqueous nasal budesonide and loratadine
Trial: 24039213
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous nasal budesonide and loratadine
Trial: 17851462
Drug: Protein hydrolysates
RxNorm normalized name: protein hydrolysates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein hydrolysates (pea, rice, soy, gluten, whey, egg) with 0.2 g hydrolysate per kg body weight and 0.2 g maltodextrin per kg body weight
Trial: 17823625
Drug: Both pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both pioglitazone and atorvastatin
Trial: 15064633
Drug: Cineole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cineole (two 100‐mg capsules three times daily)
Trial: 12692603
Drug: Etoposide (E)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide (E) at 800 mg/m²
Trial: 12692603
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 910 mg/m²
Trial: 10073771
Drug: Heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuit (n = 15)
Trial: 10073771
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Heparin-coated and Uncoated circuits)
Trial: 31221225
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine and conventional acupuncture
Trial: 31221225
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine and mind-regulating acupuncture
Trial: 26932738
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg/day for 6 months)
Trial: 24236828
Drug: Otelixizumab (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otelixizumab (3.1 mg over 8 days)
Trial: 22300416
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation (including a photo file, demonstration of equipment using a role-modelling approach, and a tour)
Trial: 22300416
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation
Trial: 20367660
Drug: Ablation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation of residual potentials as add-on therapy to circumferential pulmonary vein ablation (CPVA) + pulmonary vein electrical isolation (PVI), n = 49
Trial: 10498160
Drug: Long-term diuretic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term diuretic therapy
Trial: 10498160
Drug: No diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diuretic therapy (Control)
Trial: 6238991
Drug: Independent of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent of treatment
Trial: 30761790
Drug: NefraDoz (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NefraDoz (1 capsule three times daily for one month)
Trial: 30761790
Drug: Standard antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibacterial therapy (control group)
Trial: 26216648
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (6000 mg day(-1) of fish oil)
Trial: 26216648
Drug: Control (6000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (6000 mg day(-1) of soybean oil)
Trial: 25135060
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.1 g/kg/d)
Trial: 23816952
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 17.5% CO2
Trial: 23816952
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 35% CO2
Trial: 18354390
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 0% CO2 (control)
Trial: 16097710
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vardenafil every other day for 7 weeks after the intervention
Trial: 7500239
Drug: ePTFE interproximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePTFE interproximal membranes in combination with decalcified freeze‐dried bone (DFDBA)
Trial: 2878134
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 5 mg in 5 ml of water
Trial: 3174151
Drug: Epidural clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural clonidine 150 micrograms in 5 ml of saline
Trial: 2878134
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine 0.3 mg in 5 ml of saline
Trial: 29326420
Drug: Insulin to
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin to glucose ratios at 20 °C
Trial: 22051332
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion (VE) with normal saline (0.25 ml/kg/min for 60 min)
Trial: 19194157
Drug: Midazolam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (20 and 40 ng/ml)
Trial: 19194157
Drug: Propofol (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.45 and 0.9 microg/ml)
Trial: 19194157
Drug: Dexmedetomidine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.25 and 0.4 ng/ml)
Trial: 19194157
Drug: Thiopental (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (1.5 and 3 microg/ml)
Trial: 15070633
Drug: Three days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three days of oral amoxicillin 31‐54 mg/kg/day in three divided doses
Trial: 15070633
Drug: Five days
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five days of oral amoxicillin 31‐54 mg/kg/day in three divided doses
Trial: 9651060
Drug: Conventionally and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally and digitally subtracted aortic arch injection angiograms
Trial: 9651060
Drug: Intravenous digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous digital subtraction angiograms
Trial: 8062314
Drug: carteolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carteolol (15 mg/d)
Trial: 8062314
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 mg/d)
Trial: 3190508
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid (52, 156, and 260 mmol/l)
Trial: 24919603
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine with stepwise addition of up to three insulin glulisine injections (G + 3)
Trial: 24919603
Drug: Twice-daily premixed
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily premixed 70/30 insulin protamine-aspart/aspart (PM-2)
Trial: 24919603
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine with up to one insulin glulisine injection (G + 1)
Trial: 20109213
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg PO once daily for 5 days, repeated every 8 weeks for a total of six courses
Trial: 410230
Drug: 2% disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% disodium cromoglycate (DSCG) nasal spray
Trial: 24839145
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for overweight, Class I, and Class II obese women
Trial: 21225104
Drug: Dipyrone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (15 mg/kg)
Trial: 17535290
Drug: ANALOGUE (optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANALOGUE (optimized analogue therapy; lispro/glargine)
Trial: 17535290
Drug: CSII (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII (continuous subcutaneous insulin infusion therapy; lispro)
Trial: 17535290
Drug: EDUCATION (re-education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDUCATION (re-education with relaxation of blood glucose targets on existing conventional insulin regimen)
Trial: 15471655
Drug: Radiotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy only (not pre-treated with chemotherapy)
Trial: 11598580
Drug: Intracanal corticosteroid-antibiotic
RxNorm normalized name: antibiotics in combination with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracanal corticosteroid-antibiotic compound
Trial: 9649455
Drug: Oral beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beclomethasone dipropionate (8 mg/day) plus prednisone (1 mg.kg‐1.day‐1)
Trial: 9649455
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules plus prednisone (1 mg.kg‐1.day‐1)
Trial: 7979170
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C intake of 20 mg/kg or more
Trial: 7979170
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C intake above 20 mg/kg/day
Trial: 7979170
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C intake of 8 mg/kg/day
Trial: 3899082
Drug: Fenoterol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.2 mg)
Trial: 2898368
Drug: Salbutamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (2 x 0.1 mg)
Trial: 2898368
Drug: Terbutaline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (2 x 0.25 mg)
Trial: 2898368
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (maximal mean plasma concentration 14.9 +/- 2.2 mg l-1) after placebo inhalation
Trial: 2898368
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of theophylline and fenoterol
Trial: 27411333
Drug: Remifentanil 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2.0 ng/ml
Trial: 27411333
Drug: Remifentanil 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 3.0 ng/ml
Trial: 27411333
Drug: Remifentanil 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 4.0 ng/ml
Trial: 22487920
Drug: Local EMLA
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local EMLA cream preoperatively (Group I, N=15)
Trial: 22487920
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative preparation (Group II, N=15)
Trial: 20500126
Drug: Caffeine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (80 mg, 3x/day for 6 days followed by a challenge dose of 250 mg)
Trial: 16219950
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of orbital irradiation and systemic steroids (SRT group)
Trial: 16219950
Drug: Systemic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroids alone (ST group)